原发性肝癌转化治疗研究进展及展望

Research Progress and Prospects of Conversion Therapy for Primary Liver Cancer

原发性肝癌是临床中最常见的恶性肿瘤之一。由于其早期缺乏典型的临床表现,我国大多数病人确诊时已达中晚期,预后较差。因此通过相关治疗手段将不可切除肝癌转化为可切除肝癌的探索是十分有必要的。近年来,随着肝动脉栓塞化疗(TACE)及肝动脉灌注化疗(HAIC)等介入治疗技术的不断进步完善,新的靶向及免疫药物投入临床实验及应用,为肝癌转化治疗更新和发展带来了新的机遇和挑战。本综述旨在对目前肝癌转化治疗的现状和进展进行讨论,为肝癌的临床治疗提供一定参考。

Primary liver cancer is one of the most common malignant tumors in clinical practice. Due to the lack of typical clinical manifestations in its early stage, most patients in China are already in the middle and late stages when diagnosed, and the prognosis is poor. Therefore, it is necessary to ex-plore the transformation of unresectable hepatocellular carcinoma into resectable hepatocellular carcinoma through relevant therapeutic means. In recent years, with the continuous improvement of interventional techniques such as transcatheter arterial chemoembolization (TACE) and hepatic artery infusion chemotherapy (HAIC), new targeted and immune drugs have been put into clinical trials and clinics, which bring new opportunities and challenges for the update and development of hepatocellular carcinoma translational therapy. This review aims to discuss the current status and progress of translational therapy for hepatocellular carcinoma and provide some reference for the clinical treatment of hepatocellular carcinoma.